Phase 1 trial: Dasatinib tyrosine kinase inhibitor for residual glioma

This Phase 1 trial led by Mayo Clinic in Rochester evaluates safety, tolerability, and potential efficacy of sequential combination regimens – starting with dasatinib plus quercetin, fisetin, and temozolomide – in previously treated glioma patients with residual disease (including those with IDH mutations or MGMT methylation) using imaging and biospecimen assessments to guide individualized treatment strategies.